Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Nilsine Partners LLC

Nilsine Partners LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,489 shares of the life sciences company’s stock after buying an additional 213 shares during the quarter. Nilsine Partners LLC’s holdings in Illumina were worth $466,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after acquiring an additional 48,018 shares during the last quarter. Primecap Management Co. CA raised its holdings in shares of Illumina by 3.6% in the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after purchasing an additional 87,599 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Illumina by 4.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock worth $164,334,000 after buying an additional 54,319 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock worth $137,735,000 after buying an additional 631,294 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ILMN shares. TD Cowen raised their price objective on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Morgan Stanley dropped their price target on Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a research note on Thursday, October 17th. Barclays boosted their price target on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Finally, Royal Bank of Canada raised their price objective on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $165.63.

Illumina Trading Down 1.4 %

Shares of NASDAQ ILMN opened at $131.72 on Thursday. The stock has a market cap of $20.89 billion, a price-to-earnings ratio of -13.22 and a beta of 1.11. The business has a 50 day simple moving average of $139.05 and a 200 day simple moving average of $135.07. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the prior year, the business posted $0.33 EPS. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. On average, research analysts predict that Illumina, Inc. will post 4.13 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.